Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
Stanford University · with National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · NCT05165706
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 35–65 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 110
- US sites recruiting
- 1
- Study start
- January 31, 2019
- Record last updated
- December 4, 2024
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This 12-week controlled diet and weight intervention study seeks to define the molecular pathways that link excess body weight to the development of insulin resistance (IR). Blood, adipose and stool are sampled at three timepoints; baseline, peak weight (4 weeks) and post weight loss to monitor changes in cellular processes. Additionally, direct insulin sensitivity testing, and radiological measurement of visceral fat and intrahepatic fat content is measured at three timepoints to correlate clinical indices with cellular changes.
Being studied: Dietary Intervention Mediterranean Low Carbohydrate Diet; Dietary Intervention Standard Low Carbohydrate Diet; Dietary Intervention Standard Low Fat Diet
Conditions: Diabetes Mellitus, Type 2; PreDiabetes; Insulin Resistance; Obesity; Nonalcoholic Steatohepatitis; Nonalcoholic Fatty Liver; Diet Modification
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Age 35-65
- BMI 25-35 kg/m2
- Stable body weight
- Nondiabetic
Exclusion Criteria
Patients with;
- diabetes
- major organ disease
- history of liposuction or bariatric surgery
- active eating or psychiatric disorder
- pregnancy or lactation, heavy alcohol use
- recent change in weight (over the past 12 weeks)
- use of weight loss medication, statins, or oral steroids
Clinical screening exclusions;
- hematocrit \< 33%
- fasting glucose >/= 126 mg/dL
- blood pressure >160/100 mmHg
Recruiting US locations
Stanford University
Stanford, CA 94305
Site contact: Ekrem M Ayhan, BS · 908-619-5381 · ayhane@stanford.edu
Study contacts (from the official record)
- Ekrem M Ayhan, BS · 908-619-5381 · ayhane@stanford.edu
- Dalia Perelman, MS, RD · daliap@stanford.edu
Similar studies in California
All weight loss studies in California →- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants
AstraZeneca
- Location
- Glendale, CA + 1 other US site
- Eligibility basics
- Ages 18–55
- RecruitingHealthy volunteersPhase 1
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity.
AstraZeneca
- Location
- Glendale, CA + 1 other US site
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteersPhase 1
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Orally Administered TIX100 in Healthy Subjects
TIXiMED, Inc.
- Location
- Chula Vista, CA
- Eligibility basics
- Ages 18–70
- RecruitingHealthy volunteersPhase 1
Safety and Drug Concentrations of REGN20934 in Adults With Overweight or Obesity
Regeneron Pharmaceuticals
- Location
- Glendale, CA
- Eligibility basics
- Ages 18–65